Use of compound in preparation of drug for treatment or prevention of mycobacterium tuberculosis infection

Abstract

The present invention provides use of a rifamycin-nitroimidazole conjugate molecule, or deuterated derivatives thereof, metabolites thereof, pharmaceutically acceptable salts thereof, or prodrugs thereof in the preparation of a drug for the treatment or prevention of a disease caused by Mycobacterium tuberculosis infection. The rifamycin-nitroimidazole conjugate molecule has a structure represented by formula I. The rifamycin-nitroimidazole conjugate molecule or the deuterated derivatives thereof, the metabolites thereof, the pharmaceutically acceptable salts thereof, or the prodrugs thereof in the present invention inhibit Mycobacterium tuberculosis comprising multi-drug-resistant (MDR) and extensive drug-resistant Mycobacterium tuberculosis (XDR-TB), and then are used for treating or preventing infections and a disease caused by Mycobacterium tuberculosis.

Dependencies are inferred from the claim text.